Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -76.88%
Price change 2019 → 2020: 73.91%
Price change 2020 → 2021: -61.25%
Price change 2021 → 2022: -67.35%
Price change 2022 → 2023: 0.53%
Price change 2023 → 2024: -69.33%
Price change 2024 → 2025: 237.61%
Price change 2025 → 2026: -79.24%
Price change 2026 (year to date): -78.95%
Financial growth
Revenue CAGR (8 years): N/A
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.00
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -0.51
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 63.72% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="CRVO" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| CervoMed Inc. | – | 0.00 | – | 🔒 |
| Implanet S.A. | – | 14.66 | +5.0 % | – |
| Valbiotis S.A. | – | 0.73 | +56.9 % | – |
| Diagnostic Medical Systems S.A. | – | 0.98 | +7.0 % | – |
| Biosynex S.A. | – | 1.90 | +35.4 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by CervoMed Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2010 | 40,189 | -8.4 m | -20,926.1 % | n/a |
| 2011 | 570,476 | -22.6 m | -3,967.9 % | +1,319.5 % |
| 2012 | 374,542 | -6.9 m | -1,834.0 % | -34.3 % |
| 2013 | 71,667 | -2.5 m | -3,438.1 % | -80.9 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by CervoMed Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 37.3 m | 4.1 m | 7.8 m | 38.9 m | 20.9 m |
| Total Debt | 0 | 12.4 m | 0 | 0 | 0 |
| Net Debt | -37.3 m | 8.3 m | -7.8 m | -9.0 m | -8.2 m |
| Equity | 34.9 m | -9.0 m | 7.4 m | 39.2 m | 18.2 m |
| Total assets | 37.8 m | 4.2 m | 10.0 m | 43.1 m | 22.9 m |
| Operating cash flow | -14.5 m | -2.6 m | -7.4 m | -16.5 m | -23.4 m |
| Investments (capex) | 0 | 1 | 0 | 0 | 0 |
| Free cash-flow | -14.5 m | -2.6 m | -7.4 m | -16.5 m | -23.4 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.
Valuation and competitors
CervoMed Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| CervoMed Inc. | 21.5 m | n/a | 0.0 % |
| Gain Therapeutics, Inc. GANX | 43.9 m | n/a | 0.0 % |
| Adagene Inc. ADAG | 75.3 m | n/a | -229.6 % |
| XBiotech Inc. XBIT | 57.6 m | n/a | 0.0 % |
| OS Therapies Incorporated OSTX | 46.8 m | n/a | 0.0 % |
| Nutriband Inc. NTRB | 67.5 m | n/a | -404.1 % |
| Adicet Bio, Inc. ACET | 28.6 m | n/a | 0.0 % |
| NRx Pharmaceuticals, Inc. NRXP | 103 m | n/a | -2,336.5 % |
| Fortress Biotech, Inc. FBIO | 61.7 m | n/a | 10.8 % |
| Sector median (Nasdaq) | 20.8 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering CervoMed Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 5 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in CervoMed Inc.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 07/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about CervoMed Inc.
What is the CervoMed Inc. share price?
Latest recorded price: 1.69 USD on 13/11/2026, for a market cap of 25.6 m USD.
What is the revenue of CervoMed Inc.?
71,667 USD for fiscal year 2013, with net income of -2.5 m USD (net margin -3,438.1 %).
What do analysts say about CervoMed Inc.?
Out of 7 analysts: 7 buy or strong buy, 0 hold, 0 sell or strong sell.
Is CervoMed Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US15713L1098).
How many employees does CervoMed Inc. have?
15 full-time employees according to the latest published profile.
Who runs CervoMed Inc.?
John J. Alam is the company's chief executive.